Launch of New Interactive Investor Hub
18 July 2024
Enabling proactive
communication and enquiry support to
shareholders
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and
diagnostic applications, announces the launch of its new interactive
investor hub which is accessible from the Company’s website.
For both existing and prospective shareholders, the new interactive
investor hub brings all of the Company’s existing content into a single
integrated platform, and will enable investors and stakeholders to be
better informed and engaged, including but not limited to, the
Company’s:
- Regulatory announcements
- Reports
- Presentations
- Educational material
- Interviews
- Corporate research
The new investor hub also offers an interactive online experience,
enabling the Company’s stakeholders to comment on and ask the Fusion
team questions via a dedicated portal which the Company will monitor and
through which it will provide appropriate responses in a timely manner.
To sign up to the new interactive investor hub, stakeholders are
encouraged to:
- Visit investorhub.fusionantibodies.com
- Follow the prompts to sign up for an investor hub account
- Complete your account profile
The information disclosed pursuant to Rule 26 of the AIM Rules for
Companies will continue to be available at the Company’s website: www.fusionantibodies.com.
Adrian Kinkaid, CEO of Fusion Antibodies plc, commented:
"Engaging with our shareholders has always been fundamental at
Fusion. The launch of our new interactive investor hub marks an
exciting step forward, providing a dynamic platform for current and
potential investors to connect with us as well as to gain a
comprehensive understanding of our mission, our technology and our
business.
“The new interactive investor hub will act as a rich resource, offering video content, detailed information, and insights into our ongoing activities and future strategies. We encourage our stakeholders to explore the new investor hub and share their thoughts as we aim to enhance and refine our communication channels."
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com | |
| Adrian Kinkaid, Chief Executive
Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR | |
| Allenby Capital Limited | Tel: +44 (0) 20 3328 5656 | |
| James Reeve/Vivek Bhardwaj (Corporate
Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking) |
||
| Shard Capital Partners LLP | ||
| Damon Heath (Joint Broker) | Tel: +44 (0) 207 186 9952 | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 741 001 | |
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the development
of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18
December 2017. Fusion provides a broad range of services in antibody
generation, development, production, characterisation and optimisation.
These services include antigen expression, antibody production,
purification and sequencing, antibody humanisation using Fusion's
proprietary CDRx TM platform and the
production of antibody generating stable cell lines to provide material
for use in clinical trials. Since 2012, the Company has
successfully sequenced and expressed over 250 antibodies and
successfully completed over 200 humanisation projects and has an
international, blue-chip client base, which has included eight of the
top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and
diagnostic companies to develop innovative products in a timely and
cost-effective manner for the benefit of the global healthcare industry.
Fusion Antibodies provides a broad range of services in antibody
generation, development, production, characterisation and
optimisation.
Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new
platforms that will enable Pharma and Biotech companies get to the
clinic faster, with the optimal drug candidate and ultimately speed up
the drug development process.
*About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.